Phase II study of palliative S-1 in combination with cisplatin as second-line chemotherapy for gemcitabine-refractory pancreatic cancer patients

Oncology Letters

Volumn 3, Issue 6, 2012, Pages 1314-1318

  Kim, Hyun Jung ^a   Yun, Jina ^a   Kim, Han Jo ^a   Kim, Kyoung Ha ^a   Kim, Se Hyung ^a   Lee, Tae Hoon ^a   Lee, Sang Cheol ^a   Bae, Sang Byung ^a   Kim, Chan Kyu ^a   Lee, Nam Su ^a   Moon, Jong Ho ^a   Park, Sang Heum ^a   Lee, Kyu Taek ^a   Park, Seong Kyu ^a   Won, Jong Ho ^a   Park, Hee Sook ^a   Hong, Dae Sik ^a  

^a Soonchunhyang University   (South Korea)

Author keywords

Cisplatin; Gemcitabine refractory; Pancreatic cancer; S 1

Indexed keywords

APREPITANT; CA 19-9 ANTIGEN; CISPLATIN; DEXAMETHASONE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; FATIGUE; FEMALE; FOLLOW UP; HUMAN; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTOPENIA;

EID: 84859465101     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.637     Document Type: Article

References (27)

1. Burris HA III, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997.
2. Oettle H, Pelzer U, Stieler J, Hilbig A, et al: Oxaliplatin/folinic acid/5-fluorouracil [24h] (OFF) plus best supportive care versus best supportive care alone in second-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO 003). J Clin Oncol 23 (Suppl): 4031, 2005.
3. Nakachi K, Furuse J, Ishii H, Suzuki E and Yoshino M: Prognostic factors in patients with gemcitabine-refractory pancreatic cancer. Jpn J Clin Oncol 37: 114-120, 2007.
4. Morizane C, Okusaka T, Furuse J, et al: A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol 63: 313-319, 2009.
5. Morizane C: A case of gemcitabine-refractory pancreatic cancer responsive to second-line chemotherapy using S-1. Jpn J Clin Oncol 37: 973, 2007.
6. Todaka A, Fukutomi A, Boku N, et al: S-1 monotherapy as second-line treatment for advanced pancreatic cancer after gemcitabine failure. Jpn J Clin Oncol 40: 567-572, 2010.
7. Ueno H, Okusaka T, Ikeda M, Takezako Y and Morizane C: An early phase II study of S-1 in patients with metastatic pancreatic cancer. Oncology 68: 171-178, 2005.
8. Funakoshi A, Senju T and Sumii T: Two cases of advanced pancreatic cancer with cervical lymph node or liver metastasis responding well to S-1 monotherapy. Gan To Kagaku Ryoho 33: 1505-1509, 2006 (In Japanese).
9. Ducreux M, Rougier P, Pignon JP, et al: A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann Oncol 13: 1185-1191, 2002.
10. Rougier P, Zarba J, Ducreux M, et al: Phase II study of cisplatin and 120-hour continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinoma. Ann Oncol 4: 333-336, 1993.
11. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
12. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
13. Conroy T, Desseigne F, Ychou M, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364: 1817-1825, 2011.
14. Dahan L, Bonnetain F, Ychou M, et al: Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301). Gut 59: 1527-1534, 2010.
15. Androulakis N, Syrigos K, Polyzos A, et al: Oxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: a multicenter phase II study. Cancer Invest 23: 9-12, 2005.
16. Ulrich-Pur H, Raderer M, Verena Kornek G, et al: Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br J Cancer 88: 1180-1184, 2003.
17. Oettle H, Arnold D, Esser M, Huhn D and Riess H: Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs 11: 635-658, 2000.
18. Boeck S, Weigang-Köhler K, Fuchs M, et al: Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial. Ann Oncol 18: 745-751, 2007.
19. Pelzer U, Kubica K, Stieler I, et al: A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol 26 (Suppl 15): 4508, 2008.
20. Lubner SJ, Schelman WR, Mulkerin D, Holen KD, Seo S and LoConte NK: Phase II study of oxaliplatin, high-dose capecitabine, and sorafenib in patients with advanced pancreatic cancer. J Clin Oncol 28 (Suppl 15): 4143, 2010.
21. Starling N, Hawkes EA, Chau I, et al: A dose-escalation study of gemcitabine plus oxaliplatin in combination with imatinib in patients with gemcitabine-refractory advanced pancreatic adenocarcinoma. Ann Oncol: Jul. 12, 2011 (E-pub ahead of print).
22. Nakai Y, Isayama H, Sasaki T, et al: Impact of S-1 in patients with gemcitabine-refractory pancreatic cancer in Japan. Jpn J Clin Oncol 40: 774-780, 2010.
23. Alsamarai S, Zergebel C, Zhang J, Furuie T, Urrea PD and Saif MW: Long term survival on S-1 monotherapy in a patient with recurrent stage IV pancreatic cancer. JOP 9: 185-191, 2008.
24. Yoshino T, Fukutomi A and Boku N: Chemotherapy-naïve advanced pancreatic cancer with multiple liver metastases successfully treated by S-1 monotherapy. A case report. Gan To Kagaku Ryoho 33: 1521-1523, 2006 (In Japanese).
25. Koizumi W, Narahara H, Hara T, et al: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9: 215-221, 2008.
26. Ajani JA, Rodriguez W, Bodoky G, et al: Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 28: 1547-1553, 2010.
27. Togawa A, Yoshitomi H, Ito H, et al: Treatment with an oral fluoropyrimidine, S-1, plus cisplatin in patients who failed postoperative gemcitabine treatment for pancreatic cancer: a pilot study. Int J Clin Oncol 12: 268-273, 2007.